Clinical Trials: Active Research on Longevity Supplements
Active and recent human trials of longevity interventions — grouped by mechanism, with status, phase and a link to the registry.
This is a living map of the notable human trials now testing longevity interventions — rapamycin, senolytics, NAD+ boosters, urolithin A, spermidine and metformin — against aging, frailty and healthspan endpoints. It is deliberately restricted to registered, mostly placebo-controlled studies in people; animal work and marketing claims are excluded. Note what is missing as much as what is here: the field's most-hyped molecules are still largely unproven in humans, and the landmark metformin trial (TAME) has yet to fully launch. Trials are grouped by intervention; each links to its ClinicalTrials.gov record.
mTOR
Everolimus (rapalog) — mTORC1 Inhibition for Geroprotection
Tests whether low-dose everolimus improves insulin sensitivity and immune aging in healthy older adults — one of the few placebo-controlled human geroprotection trials of an mTOR inhibitor.
NCT05835999 on ClinicalTrials.gov →Rapamycin — Ovarian Aging
Asks whether weekly rapamycin slows ovarian aging and extends reproductive lifespan in perimenopausal women — a landmark question for female healthspan.
NCT05836025 on ClinicalTrials.gov →Rapamycin + fasting-mimicking diet — REVERSE
Combines intermittent rapamycin with a Prolon fasting-mimicking diet to move aging biomarkers — small and early, but a real test of the popular rapamycin-plus-fasting stack.
NCT07354620 on ClinicalTrials.gov →Senolytic
Dasatinib + Quercetin / Fisetin — SEN-SURVIVORS
Senolytics to clear senescent cells and reduce frailty in adult survivors of childhood cancer — among the most rigorous human senolytic trials.
NCT04733534 on ClinicalTrials.gov →Fisetin — FIRST (peripheral artery disease)
Tests whether the senolytic fisetin improves walking ability and reduces senescence in PAD — a focused, placebo-controlled efficacy signal.
NCT06399809 on ClinicalTrials.gov →Fisetin + exercise — frailty after breast cancer
Pairs fisetin with exercise against accelerated aging after cancer therapy — larger and longer than most senolytic pilots.
NCT06113016 on ClinicalTrials.gov →Low-dose Fisetin — healthy aging
One of the few senolytic trials in generally healthy older adults rather than a disease population — closer to how people actually use fisetin.
NCT07195318 on ClinicalTrials.gov →NAD
Nicotinamide Riboside — NADage (frailty)
Randomized test of NAD+ replenishment on frailty in older adults — the kind of hard-endpoint NAD trial the field has largely lacked.
NCT06208527 on ClinicalTrials.gov →NMN — Quzhou aging cohort
A large placebo-controlled NMN trial in middle-aged and older adults — notable for its size in a field dominated by small studies.
NCT06592859 on ClinicalTrials.gov →Nicotinamide Riboside — blood pressure & arterial stiffness
From a leading vascular-aging lab: whether NR lowers systolic blood pressure and arterial stiffness — concrete cardiovascular endpoints, not just biomarkers.
NCT03821623 on ClinicalTrials.gov →Urolithin
Urolithin A — glucose metabolism (age 55+)
NIH/NIA-funded test of whether urolithin A improves glucose metabolism in older adults — unusual government-grade rigor for a supplement.
NCT06274749 on ClinicalTrials.gov →Urolithin A (Mitopure) — muscle strength
A confirmatory RCT of urolithin A on muscle strength in healthy middle-aged adults — the mitophagy-and-muscle story tested head-on (note: run by the ingredient's maker).
NCT07231783 on ClinicalTrials.gov →Metformin
Metformin — anti-ageing in COPD
A large phase 3 asking whether metformin's proposed anti-ageing effects translate into a hard respiratory-disease outcome.
NCT06999343 on ClinicalTrials.gov →GLP-1 (semaglutide / tirzepatide) ± metformin — aging clock
Measures whether GLP-1 drugs shift an epigenetic aging clock in obese adults — the first wave of GLP-1-as-geroprotector data.
NCT07293325 on ClinicalTrials.gov →Spermidine
Spermidine — sleep & early cognitive decline
Tests spermidine, an autophagy inducer, on sleep and cognition in people with subjective or mild cognitive decline.
NCT07383311 on ClinicalTrials.gov →Multi
Multi-supplement + lifestyle — PROMETHEUS (Singapore)
A Singapore precision-geromedicine pilot combining creatine, urolithin A, NMN, whey protein and lifestyle — small, but a model for personalized, measured stacks.
NCT07451496 on ClinicalTrials.gov →